Pfizer (PFE)
24.62
+0.32 (1.32%)
NYSE · Last Trade: Jun 11th, 11:30 AM EDT
Detailed Quote
Previous Close | 24.30 |
---|---|
Open | 24.33 |
Bid | 24.61 |
Ask | 24.62 |
Day's Range | 24.33 - 24.69 |
52 Week Range | 20.92 - 31.54 |
Volume | 12,700,490 |
Market Cap | 138.04B |
PE Ratio (TTM) | 17.84 |
EPS (TTM) | 1.4 |
Dividend & Yield | 1.720 (6.99%) |
1 Month Average Volume | 41,345,757 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END
Via FinancialNewsMedia · June 11, 2025
Steady growth and dividend increases over decades can make investors remarkably wealthy.
Via The Motley Fool · June 11, 2025
PALM BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates there will be over 35 million new cancer cases by 2050, a massive 77% increase from the estimated 20 million cases in 2022. This rising occurrence of cancer has been attributed to lifestyle changes in an increasingly geriatric population in both developed countries and emerging economies. Environmental factors such as pollution and the high penetration of microplastics, a potential carcinogen, are also contributing to the growing number of cancer cases. As the global burden of cancer continues to go up, government and private organizations are increasing funding in both healthcare infrastructure and investment into research and development of therapeutics and potential cures for various kinds of cancers. Many federal early detection programs have been launched with large players in the pharmaceutical sector looking to increase the number of clinical trials and drug discovery studies undertaken. These innovations are propelling market expansion, with the sector expected to witness significant growth in the coming years as new technologies and therapies continue to emerge. A new research report from BioSpace, said the global oncology market size was USD 321.19 billion in 2024, and calculated at USD 356.20 billion in 2025 is expected to reach around USD 903.81 billion by 2034, growing at a CAGR of 10.9% for the forecasted period. the development of the global healthcare infrastructure and cancer continuing to be one of the leading causes of death worldwide drives growth in the global oncology market. Active oncology biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), BioNTech SE (NASDAQ: BNTX), Arvinas, Inc. (NASDAQ: ARVN), Pfizer Inc. (NYSE: PFE).
By FN Media Group LLC · Via GlobeNewswire · June 11, 2025
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.
Via Investor's Business Daily · June 10, 2025
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.
Via The Motley Fool · June 10, 2025
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.
Via Benzinga · June 10, 2025
Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust."
Via Stocktwits · June 10, 2025
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition.
Via Investor's Business Daily · June 9, 2025
The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36.
Via Stocktwits · June 9, 2025
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
Via Chartmill · June 9, 2025
The meeting follows an executive order from President Trump last month, which directed drugmakers to lower medicine prices to the levels paid by other high-income countries.
Via Stocktwits · June 9, 2025
Via Benzinga · June 9, 2025
Via The Motley Fool · June 8, 2025

Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients
Via Benzinga · June 6, 2025

U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health experts call a dichotomy in his approach to healthcare policy.
Via Benzinga · June 6, 2025

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –
By Arvinas Inc. · Via GlobeNewswire · June 6, 2025

Via The Motley Fool · June 5, 2025

A volatile stock market represents an ideal opportunity for long-term investors to pounce.
Via The Motley Fool · June 5, 2025
Hundreds Sue Pfizer Over Birth Control Jabs Linked to Brain Tumors
American pharmaceutical and biotech company Pfizer has been sued by hundreds of American and UK women after a recent study revealed that a contraceptive injection developed by the company increased their risk of developing brain tumors significantly. Four hundred American women have already filed the lawsuit in a Florida county, and around 200 women from the UK are also considering suing the pharmaceutical firm, the Daily Mail reports.
Via Investor Brand Network · June 4, 2025

Nearly 80% of S&P 500 firms beat Q1 earnings forecasts. Profit growth hit 13.3%, led by tech and health care, says FactSet.
Via Benzinga · June 3, 2025

Apple and Cisco could generate surprising gains over the next few years.
Via The Motley Fool · June 3, 2025

Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.
Via The Motley Fool · June 3, 2025

Bristol Myers Squibb just agreed to shower BioNTech with cash.
Via The Motley Fool · June 2, 2025

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time.
By Pfizer Inc. · Via Business Wire · June 2, 2025